Clinical Trial Update: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [Phase 1, Phase 2]

View source ↗

Summary

KYSA-1, an anti-CD19 CAR T-cell therapy, is being studied in refractory lupus nephritis in Phase 1/2 and is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• KYSA-1

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING